GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » JW (Cayman) Therapeutics Co Ltd (FRA:JNY) » Definitions » Change In Receivables

JW (Cayman) Therapeutics Co (FRA:JNY) Change In Receivables : €0.00 Mil (TTM As of Jun. 2024)


View and export this data going back to 2023. Start your Free Trial

What is JW (Cayman) Therapeutics Co Change In Receivables?

JW (Cayman) Therapeutics Co's change in receivables for the quarter that ended in Jun. 2024 was €0.00 Mil. It means JW (Cayman) Therapeutics Co's Accounts Receivable stayed the same from Dec. 2023 to Jun. 2024 .

JW (Cayman) Therapeutics Co's change in receivables for the fiscal year that ended in Dec. 2023 was €0.68 Mil. It means JW (Cayman) Therapeutics Co's Accounts Receivable declined by €0.68 Mil from Dec. 2022 to Dec. 2023 .

JW (Cayman) Therapeutics Co's Accounts Receivable for the quarter that ended in Jun. 2024 was €0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. JW (Cayman) Therapeutics Co's Days Sales Outstanding for the six months ended in Jun. 2024 was 0.00.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. JW (Cayman) Therapeutics Co's liquidation value for the six months ended in Jun. 2024 was €50.77 Mil.

JW (Cayman) Therapeutics Co Change In Receivables Historical Data

The historical data trend for JW (Cayman) Therapeutics Co's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

JW (Cayman) Therapeutics Co Change In Receivables Chart

JW (Cayman) Therapeutics Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Change In Receivables
Get a 7-Day Free Trial - - - -0.72 0.68

JW (Cayman) Therapeutics Co Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

JW (Cayman) Therapeutics Co Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

JW (Cayman) Therapeutics Co  (FRA:JNY) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

JW (Cayman) Therapeutics Co's Days Sales Outstanding for the quarter that ended in Jun. 2024 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=0/11.117*91
=0.00

2. In Ben Graham's calculation of liquidation value, JW (Cayman) Therapeutics Co's accounts receivable are only considered to be worth 75% of book value:

JW (Cayman) Therapeutics Co's liquidation value for the quarter that ended in Jun. 2024 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=111.284-63.756+0.75 * 0+0.5 * 6.48
=50.77

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

JW (Cayman) Therapeutics Co Change In Receivables Related Terms

Thank you for viewing the detailed overview of JW (Cayman) Therapeutics Co's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

JW (Cayman) Therapeutics Co Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » JW (Cayman) Therapeutics Co Ltd (FRA:JNY) » Definitions » Change In Receivables
Comparable Companies
HKSE:02197 HKSE:02185 HKSE:06996 HKSE:06998 HKSE:03681 HKSE:01228 HKSE:02142 HKSE:09939 HKSE:01875 HKSE:00690 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
JWCTF:USA 02126:Hong Kong
Address
No. 699 Zhong Ke Road, 5F, Building B, Pudong New District, Shanghai, CHN
Website
https://www.jwtherapeutics.com
JW (Cayman) Therapeutics Co Ltd is a clinical-stage cell therapy company in China. It focuses on developing, manufacturing, and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors. Its lead product candidate is relmacabtagene autoleucel, which is a potential superior anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy intended for the treatment of a range of hematological cancers.

JW (Cayman) Therapeutics Co Headlines

No Headlines